Huachun Zou1, Andrew E Grulich2, Alyssa M Cornall3, Sepehr N Tabrizi4, Suzanne M Garland4, Garrett Prestage5, Catriona S Bradshaw6, Jane S Hocking7, Andrea Morrow8, Christopher K Fairley6, Marcus Y Chen6. 1. School of Population and Global Health, University of Melbourne, Melbourne, Australia; Melbourne Sexual Health Centre, Alfred Health, Melbourne, Australia. Electronic address: rolfe1234@gmail.com. 2. Kirby Institute, University of New South Wales, Sydney, Australia. 3. Department of Microbiology and Infectious Diseases, Royal Women's Hospital, Melbourne, Australia; Murdoch Children Research Institute, Melbourne, Australia. 4. Department of Microbiology and Infectious Diseases, Royal Women's Hospital, Melbourne, Australia; Murdoch Children Research Institute, Melbourne, Australia; Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, Australia. 5. Kirby Institute, University of New South Wales, Sydney, Australia; Australian Research Centre in Sex, Health and Society, La Trobe University, Melbourne, Australia. 6. School of Population and Global Health, University of Melbourne, Melbourne, Australia; Melbourne Sexual Health Centre, Alfred Health, Melbourne, Australia; Central Clinical School, Monash University, Melbourne, Australia. 7. Centre for Women's Health, Gender and Society, University of Melbourne, Melbourne, Australia. 8. Melbourne Sexual Health Centre, Alfred Health, Melbourne, Australia.
Abstract
BACKGROUND: HPV vaccination of men who have sex with men (MSM) prior to the commencement of sexual activity would have the maximum impact on preventing HPV and anal cancer in this population. However, knowledge and attitudes towards HPV vaccination among very young MSM have not been previously studied. METHODS: Two hundred MSM aged 16 to 20 were recruited via community and other sources. Participants were asked about their knowledge and attitudes towards HPV and HPV vaccination. RESULTS: Most (80%, 95% confidence interval (CI) 72.2-87.2%) men were not willing to purchase the vaccine because of its cost (AUD$450). However, if the vaccine was offered to MSM free of charge, 86% (95% CI: 80-90%) reported they would be willing to disclose their sexuality to a health care provider in order to obtain the vaccine. Over half (54%, 95%: 47-61%) of men would only be willing to disclose their sexuality to receive the HPV vaccine after their first experience of anal intercourse. The age at first insertive anal intercourse and the age at first receptive anal intercourse were 0.21 (IQR: -2.5 to 3.2) and 0.17 (IQR: -2.9 to 2.7) years earlier than the age that men would be willing to disclose their sexuality to receive the HPV vaccine, respectively. Willingness to receive the vaccine at a younger age was associated with younger age at first insertive anal intercourse. CONCLUSION: Overall, very young MSM expressed high acceptance of HPV vaccination. Early, opportunistic vaccination of very young MSM may be feasible in settings where very young MSM have not been vaccinated through universal programs targeting school aged males. However, given HPV infections occur early on, the effectiveness of this approach will be less than vaccination targeting school aged boys.
BACKGROUND: HPV vaccination of men who have sex with men (MSM) prior to the commencement of sexual activity would have the maximum impact on preventing HPV and anal cancer in this population. However, knowledge and attitudes towards HPV vaccination among very young MSM have not been previously studied. METHODS: Two hundred MSM aged 16 to 20 were recruited via community and other sources. Participants were asked about their knowledge and attitudes towards HPV and HPV vaccination. RESULTS: Most (80%, 95% confidence interval (CI) 72.2-87.2%) men were not willing to purchase the vaccine because of its cost (AUD$450). However, if the vaccine was offered to MSM free of charge, 86% (95% CI: 80-90%) reported they would be willing to disclose their sexuality to a health care provider in order to obtain the vaccine. Over half (54%, 95%: 47-61%) of men would only be willing to disclose their sexuality to receive the HPV vaccine after their first experience of anal intercourse. The age at first insertive anal intercourse and the age at first receptive anal intercourse were 0.21 (IQR: -2.5 to 3.2) and 0.17 (IQR: -2.9 to 2.7) years earlier than the age that men would be willing to disclose their sexuality to receive the HPV vaccine, respectively. Willingness to receive the vaccine at a younger age was associated with younger age at first insertive anal intercourse. CONCLUSION: Overall, very young MSM expressed high acceptance of HPV vaccination. Early, opportunistic vaccination of very young MSM may be feasible in settings where very young MSM have not been vaccinated through universal programs targeting school aged males. However, given HPV infections occur early on, the effectiveness of this approach will be less than vaccination targeting school aged boys.
Authors: Jonathan M Raviotta; Mary Patricia Nowalk; Chyongchiou Jeng Lin; Hsin-Hui Huang; Richard K Zimmerman Journal: Am J Mens Health Date: 2014-11-11
Authors: Pamina M Gorbach; Ryan Cook; Beau Gratzer; Thomas Collins; Adam Parrish; Janell Moore; Peter R Kerndt; Richard A Crosby; Lauri E Markowitz; Elissa Meites Journal: Sex Transm Dis Date: 2017-07 Impact factor: 2.830
Authors: Allen Lin; Koh J Ong; Peter Hobbelen; Eleanor King; David Mesher; W John Edmunds; Pam Sonnenberg; Richard Gilson; Irenjeet Bains; Yoon H Choi; Clare Tanton; Kate Soldan; Mark Jit Journal: Clin Infect Dis Date: 2017-03-01 Impact factor: 9.079
Authors: E Marra; C J Alberts; G D Zimet; T G W M Paulussen; T Heijman; A A Hogewoning; G J B Sonder; J S Fennema; H J C de Vries; M F Schim van der Loeff Journal: Papillomavirus Res Date: 2016-11-05